Clinical Trials
31 trialsStudy to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
Novartis
Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant
Mayo Clinic
AGAVE-201
Syndax Pharmaceuticals
Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease
National Institutes of Health Clinical Center (CC)
REACH 5
Novartis
Autologous Adipose-Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury
Hope Biosciences Research Foundation
Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors
Novartis
Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia
Gruppo Italiano Malattie EMatologiche dell'Adulto
ACALLO
Polish Lymphoma Research Group
Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy
Sanofi
Ruxolitinib for Newly Diagnosed Bronchiolitis Obliterans Syndrome
First Affiliated Hospital of Zhejiang University
PT-CY With or Without Low-dose ATG for Lymphoid Malignancies Undergoing Allo-HSCT
Shanghai Jiao Tong University School of Medicine
DIALOG
Novartis
Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia Failing TKIs Therapy
University of Milano Bicocca
A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis
Eli Lilly and Company
A Study in Participants With Moderate to Severe Psoriasis
Eli Lilly and Company
Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid Leukemia
Fundación Teófilo Hernando, Spain
ProT4
University College, London
Study to Evaluate Safety and Efficacy of Oral MP1032 in Psoriasis Patients
MetrioPharm AG
Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML)
M.D. Anderson Cancer Center
A Study Comparing Oxycodone to Oxycodone/Naloxone in Moderate to Severe, Chronic Cancer Pain
Mundipharma Research GmbH & Co KG
WIN
University Hospital Southampton NHS Foundation Trust
Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia
National Institutes of Health Clinical Center (CC)
Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)
Bristol-Myers Squibb
Revlimid® as Consolidation Treatment Chronic Lymphocytic Leukemia
University of California, San Diego
Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Gilead Sciences
Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia
University of Pittsburgh
A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia
Mirati Therapeutics Inc.
Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia
Sanofi
Pentostatin for High Risk and Refractory Chronic Graft Versus Host Disease in Children
Ann & Robert H Lurie Children's Hospital of Chicago
CRC005
Chronic Lymphocytic Leukemia Research Consortium